Liz Parrish, CEO of BioViva, speaks about helping people live longer healthier lives by using gene and cell therapies. Liz was speaking at Norways NRK TV show Trygdekontoret.
Liz Parrish interview
Liz Parrish speaks at People Unlimited on transcending the aging paradigm with gene therapy
Elizabeth Parrish spoke at People Unlimited’s March Weekend Event in our Leaders of Radical Life Extension speaker series on transcending the aging paradigm with gene therapy.
Elizabeth is the CEO of BioViva USA Inc ™, which is committed to building gene therapies to eradicate disease and extend healthy life. She is a board member of Radish Medical Solutions and founder of Biotrove Investments and media. She is actively involved in international educational media via the International Longevity Alliance, of which she is a board member and the American Longevity Alliance, on which she serves as Secretary.
People Unlimited was delighted to host Elizabeth, as we continue our speaker series featuring some of the most definitive voices in radical life extension, including Dr. Bill Andrews, Max More, and Aubrey De Grey.
BioViva CEO Liz Parrish on Singularity 1on1: Gene Therapy is NOT a Monstrous Science
BioViva‘s CEO Liz Parrish is a fire-starter and probably not everyone’s favorite person. But if your goal is as bold as defeating aging then you’ll have to break some eggs. And so feel as you might but I have to admit that Parrish is definitely one of my favorite people – not only for the scientific work that she does but also because she is a fun, passionate and fully committed individual that inspires me. Thus it was no surprise that, despite some technical difficulties with my set up, I had a total blast interviewing Liz for my Singularity 1on1 podcast.
During our 80 min conversation with Liz Parrish we cover a variety of interesting topics such as: her personal goals and motivations; how she started with the intent to cure childhood disease and ended up in the campaign to defeat aging; BioViva and its mission; being a fire-starter, vegetarian, not everyone’s favorite person and sticking to your choices; the campaign to cure Alzheimer’s Disease; what is gene therapy, how it works and why it is so promising; the definition of aging; the ethics in genetics; medicine and human rights; why telomerase therapy in humans is the most exciting therapy…
My favorite quote from this interview with Elizabeth Parrish is this:
“There is no time like the present. We can’t wait another 20 years… Starting now is the time to start.”
How Can Life Extension Become as Popular as the War on Cancer? - MILE Panel
What can be done to raise public support for the pursuit of indefinite life extension through medicine and biotechnology to the same level as currently exists for disease-specific research efforts aimed at cancers, heart disease, ALS, and similar large-scale nemeses? In this panel discussion, set to occur on October 1, 2015 – International Longevity Day – http://www.longevityforall.org/intern... - Mr. Stolyarov asks notable life-extension supporters to provide input on this vital question and related areas relevant to accelerating the pursuit of indefinite longevity.
This panel is coordinated in conjunction with MILE, the Movement for Indefinite Life Extension – https://www.facebook.com/movementfori....
View the presentation slides prepared by Sven Bulterjis, “Aging Research Needs Marketing”: http://rationalargumentator.com/Bulte...
Also see a statement prepared by Peter Rothman for this event: http://www.rationalargumentator.com/i.... Read the announcement by Keith Comito – “The Starting on October 1 – International Longevity Day” - http://www.lifespan.io/the-lifespanch...
Panelists: Adam Alonzi, Sven Bulterjis, Keith Comito, Roen Horn, B. J. Murphy, and Elizabeth Parrish
Read more about the panelists on the event page here: https://plus.google.com/b/110849996909288445310/events/cqq9aslu0909q9uje36m0ev5d90
Liz Parrish - Bioviva - Ending Ageing through Gene Therapy
Liz Parrish on Gene Therapy and how to counter the effects of ageing. She discusses using being the first patient of Bioviva - what was involved in the gene therapy and how she is feeling now - what kinds of test feedback Bioviva will be looking for to help determine the efficacy of the gene therapy treatment. Gaps between research findings and therapies being taken to market is often down to cumbersome regulation. Further she discusses how telemorase maintains healthy telomere length and how telomeres help protect from cell damage, and some of the downstream effects of shortening telomeres. Muscle mass is required to avoid diseases and accidents related to muscular dystrophy - part of her gene therapy is related to rejuvenating healthy muscle tissue. In around four more months, the effects of the gene therapy on Liz's muscle mass will be tested further.
Media responses to human testing in gene therapy are discussed.
Bioviva Science: http://www.bioviva-science.com